See the DrugPatentWatch profile for ogsiveo
How Ogsiveo Works Against Tumors
Ogsiveo (nirogacestat) is an oral gamma secretase inhibitor that blocks the Notch signaling pathway, a key driver in desmoid tumors. It prevents gamma secretase from cleaving Notch receptors, halting the release of the intracellular Notch domain (NICD). Without NICD entering the nucleus, it cannot activate genes promoting tumor cell proliferation and survival. This starves desmoid tumors—rare, non-cancerous but aggressive fibrous growths—of growth signals, leading to tumor shrinkage or stabilization.[1][2]
Clinical trials showed Ogsiveo reduced tumor size by at least 20% in 41% of patients (vs. 8% on placebo) and slowed progression.[3]
Which Tumors Does It Target?
Approved by FDA in November 2023 for adult patients with progressing desmoid tumors not amenable to surgery. Not indicated for other cancers, though gamma secretase inhibition has been studied in ovarian, breast, and multiple myeloma tumors in early research.[1][4]
Common Side Effects Patients Experience
Fatigue (71%), nausea (49%), diarrhea (42%), ovarian dysfunction or amenorrhea (75% in premenopausal women), and hair loss (28%). Most are manageable; monitoring includes ovarian reserve tests.[1][3]
How It Differs from Surgery or Other Treatments
Desmoid tumors often recur after surgery (up to 70% rate). Ogsiveo offers a non-surgical option, outperforming placebo in progression-free survival (hazard ratio 0.29). Unlike chemotherapy or tyrosine kinase inhibitors (e.g., sorafenib), it specifically targets Notch without broad cytotoxic effects.[3][5]
When Does the Patent Expire?
Ogsiveo holds patents through at least 2039 in the US, covering the compound and methods of use. No generics expected soon; check DrugPatentWatch.com for updates on challenges or extensions.[6]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216248s000lbl.pdf
[2] SpringWorks Therapeutics: https://springworkstx.com/our-science/
[3] NEJM DeFi Trial (2023): https://www.nejm.org/doi/full/10.1056/NEJMoa2304969
[4] ClinicalTrials.gov (NCT-related studies)
[5] ASCO Post on desmoid management
[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/OGSIVEO